SCHEMBL2799541

SCHEMBL2799541

BrC1C2CC3CC(C2)CC1C3.[Zn]

nearest known ligand 0.42

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.42
EPHX2 P34913 1/20 0.32
HSD11B1 P28845 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1073033 0.96 CYP2C9 (0.44) CYP2C9EPHX2HSD11B1
Methyl Alcohol SCHEMBL29101469 0.87 CYP2C9 (0.45) CYP2C9EPHX2HSD11B1
SCHEMBL2745869 0.73 P2RX7 (0.35) CYP2C9
SCHEMBL9215201 0.71 P2RX7 (0.34) CYP2C9
Adamantane SCHEMBL28667997 0.71 CYP2C9 (0.43) CYP2C9EPHX2
SCHEMBL4054861 0.67 LMNA (0.33)
SCHEMBL2214844 0.67 CYP2C9 (0.44) CYP2C9EPHX2HSD11B1
Adamantane SCHEMBL12761 0.66 CYP2C9 (0.46) CYP2C9EPHX2HSD11B1
Adamantane SCHEMBL1527414 0.66 CYP2C9 (0.46) CYP2C9EPHX2HSD11B1
Adamantane SCHEMBL29707714 0.66 CYP2C9 (0.46) CYP2C9EPHX2HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002617-A1 C1 SYMMETRIC METALLOCENE CATALYSTS TAILORED FOR PRODUCTION OF VINYL-TERMINATED POLYPROPYLENE OLIGOMERS AND MACROMONOMERS ExxonMobil Technology and Engineering Company (US) 2025-01-02 US disclosed
EP-4396246-A1 C1 SYMMETRIC METALLOCENE CATALYSTS TAILORED FOR PRODUCTION OF VINYL-TERMINATED POLYPROPYLENE OLIGOMERS AND MACROMONOMERS ExxonMobil Chemical Patents Inc. (US) 2024-07-10 EP disclosed
WO-2023034889-A1 C1 SYMMETRIC METALLOCENE CATALYSTS TAILORED FOR PRODUCTION OF VINYL-TERMINATED POLYPROPYLENE OLIGOMERS AND MACROMONOMERS EXXONMOBIL CHEMICAL PATENTS INC. (US) 2023-03-09 WO disclosed
US-20100168077-A1 Novel Pyridine Derivatives, Processes for Preparing Them, Pharmaceutical Compositions Thereof UCB PHARMA, S.A. (BE) 2010-07-01 US disclosed
EP-2144877-A1 NOVEL PYRIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM, PHARMACEUTICAL COMPOSITIONS THEREOF UCB Pharma, S.A. (BE) 2010-01-20 EP disclosed
WO-2008122378-A1 NOVEL PYRIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM, PHARMACEUTICAL COMPOSITIONS THEREOF UCB PHARMA, S.A. (BE) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168077-A1 Novel Pyridine Derivatives, Processes for Preparing Them, Pharmaceutical Compositions Thereof CYP4B1, CYP3A4, CYP2C19 CYP2C9 10/4885EPHX2 1314/4885HSD11B1 2689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.